Introduction
The metabolic syndrome is characterized by the occurrence of cardiovascular risk factors like type 2 diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein cholesterol (HDL). Central obesity and insulin resistance, the syndrome’s underlying issues, further heighten the risk of cardiovascular disease. Additionally, novel risk factors include biomarkers indicating chronic inflammation (C-reactive proteins), increased oxidant stress, thrombophilia, and endothelial dysfunction. Individuals with metabolic syndrome face a higher risk of developing atherosclerosis and experiencing cardiovascular events. The risk is particularly pronounced in women with the syndrome, and individuals with pre-existing diabetes, cardiovascular disease (CVD), and elevated CRP.
What Is Metabolic Syndrome?
The metabolic syndrome (MetS) is characterized by the presence of cardiovascular risk factors linked to obesity, such as abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, reduced HDL cholesterol, and/or hypertension. Initially, insulin resistance was a central focus in conceptualizing metabolic syndrome, coinciding with the listed features. Each metabolic syndrome component independently contributes to CVD risk factors and their combination heightens the likelihood and severity of cardiovascular conditions. These encompass microvascular dysfunction, coronary atherosclerosis, calcification, cardiac dysfunction, myocardial infarction, and heart failure.
Metabolic syndrome can occur due to genetic, environmental, and lifestyle factors such as poor dietary choices, sedentary habits, and elevated body mass. The global rise in its prevalence is linked to escalating rates of obesity, particularly abdominal obesity, and type 2 diabetes. Pathophysiological mechanisms driving this increase involve heightened insulin resistance, advancing age, and central adiposity.
Effective management of metabolic syndrome involves lifestyle modifications. Central to treatment are weight loss, proper nutrition, and regular physical activity. Targeted therapeutic approaches to address modifiable risk factors like high blood pressure or dyslipidemia should align with established guidelines. Timely detection and intervention are crucial in mitigating the risk of associated cardiovascular complications.
How Does Metabolic Syndrome Affect Cardiovascular Health?
The association between obesity and hypertension has led to extensive research exploring the impact of obesity on the cardiovascular system. Chronic increases in body weight and adiposity induce neuro-hormonal changes, activating the renin-angiotensin-aldosterone system, altering adipocytokines and pro-inflammatory cytokine levels, and increasing sympathetic nervous system activity. This sympathetic activation contributes to cardiovascular abnormalities and metabolic imbalances, such as increased heart rate, renal sodium retention, and insulin resistance.
While insulin resistance is no longer part of the clinical definition of metabolic syndrome (MetS), it still underlies MetS features like dysglycemia, elevated fatty acid levels, and hyperinsulinemia. Epidemiological studies consistently associate hyperinsulinemia with obesity-related heart disease. Research on insulin resistance's metabolic physiology reveals its role in cellular resistance to glucose metabolism and abnormalities in insulin receptor signaling.
Obesity-related changes in cardiac function are termed the 'cardiomyopathy of obesity.' Studies, like the Multi-Ethnic Study of Atherosclerosis (MESA), show associations between body mass index and left ventricular end-diastolic volume. Obesity often results in concentric left ventricular hypertrophy and subclinical diastolic/systolic dysfunction. These changes impact outcomes following cardiac interventions, and alterations in myocardial contractile function are observed in obesity/MetS.
Molecular mechanisms underlying this cardiac phenotype involve alterations in myocardial Ca2+ handling, with changes in SERCA2A and ryanodine receptors. Modifications in the regulation of myocardial titin are also explored. Progressive vascular disease may further influence these changes through atherosclerotic and microvascular dysfunction.
Microvascular dysfunction in obesity affects various vascular beds, impacting tissue perfusion in the heart, kidney, brain, and skeletal muscle. Coronary microvascular dysfunction is linked to adverse cardiovascular events. Obesity and MetS alter microvascular tone and density, contributing to impaired oxygen delivery and metabolism in different tissues.
Myocardial metabolism in obesity involves dysregulation of fuel substrate selection. The heart, preferring fatty acids, exhibits increased fatty acid uptake and oxidation in obesity. Insulin resistance contributes to abnormal myocardial metabolism, impacting glucose uptake and insulin's regulatory functions: adipokines, systemic inflammation, and adipose-derived factors further influence myocardial fuel selection.
Atherosclerotic disease and vascular calcification are accelerated in obesity and MetS, leading to an increased risk of coronary heart disease. Adipokines may serve as molecular links between adiposity and vascular disease. Coronary perivascular adipose tissue and locally produced adipokines may influence vascular pathophysiology, presenting potential therapeutic targets.
Obesity and MetS contribute to two distinct cardiovascular diseases: congestive heart failure and atherosclerotic heart disease. Diastolic dysfunction is predominant in obesity-related heart failure. Atherosclerotic heart disease risk is elevated in obesity, with evidence supporting the benefits of surgically induced weight loss in reducing cardiovascular risk. Therapies targeting metabolic abnormalities, such as GLP-1 mimetics, are under investigation for atherosclerotic heart disease in obesity.
The correlation between obesity and hypertension has spurred research into the effects of obesity on the cardiovascular system. Chronic weight gain triggers neuro-hormonal changes and adaptation in the cardiovascular system, including activation of the renin-angiotensin-aldosterone system, altered levels of adipocytokines and pro-inflammatory cytokines, and activation of the sympathetic nervous system. This can lead to an increase in heart rate, blood pressure, and cardiac output. Insulin resistance, though no longer a clinical definition of metabolic syndrome (MetS), still contributes to its features, such as dysglycemia and elevated fatty acid levels. Insulin resistance affects fuel selection, leading to cellular resistance to glucose metabolism and abnormalities in mitochondrial function. These changes in metabolism and hormonal regulation contribute to cardiac abnormalities, including concentric left ventricular and impaired contractile function, often referred to as the cardiomyopathy of obesity. Microvascular dysfunction is also common in obesity and MetS, affecting various organs including the heart, kidneys, brain, and skeletal muscle. These alterations in microvascular function contribute to tissue hypoxia and metabolic imbalance. Impaired dilator/constrictor tone, endothelial dysfunction, and alterations in vascular channels further exacerbate vascular complications.
Three decades of concentrated research have revealed a strong association between increasing obesity levels and the MetS with accelerated atherosclerosis and a higher incidence of coronary heart disease. Individuals with MetS or diabetes often exhibit adverse plaque composition, including increased plaque burden, necrotic core, and calcium content, which contribute to elevated cardiovascular risk. Adipokines play various roles in insulin sensitivity, inflammation, coagulation, and vascular function, and may influence vascular pathophysiology.
Atherosclerotic heart disease in obesity has been recognized for decades, with preventive strategies focusing on managing risk factors and, when necessary, revascularization. Weight loss intervention, including lifestyle changes, medications, and bariatric surgery, can mitigate cardiovascular risk factors associated with MetS components.
The genetic and molecular factors underlying cardiovascular perturbations in metabolic syndrome are complex and interconnected, akin to the physiological changes observed in obesity and MetS. Advances in high-throughput molecular methodologies, such as omics methods assessing genetics, nucleic acids, proteins, or metabolites, offer promising avenues for gaining insights into the biological processes involved.
Conclusion
The contributing factors to metabolic syndrome have an impact on cardiovascular health. The combination of obesity, impaired glucose regulation, dyslipidemia, and hypertension amplifies the risk of atherosclerosis and CVDs. lifestyle interventions, including weight management, proper nutrition, and physical activity, emerge as pivotal in mitigating this risk. Timely detection and management of modifiable risk factors are crucial in preventing associated cardiovascular complications.
